European Penny Stock Opportunities For September 2026

European markets have experienced volatility recently, driven by escalating tensions in the Middle East that pushed oil and natural gas prices higher, which in turn fueled inflation concerns and influenced bond yields. Amid these market fluctuations, penny stocks—though often considered a relic of past investment trends—continue to present intriguing opportunities for those looking to invest in smaller or newer companies. These stocks can offer surprising value when backed by strong financials, providing a unique blend of potential growth and stability that may appeal to investors seeking under-the-radar opportunities.

Here we highlight a subset of our preferred stocks from the screener.

Biohit Oyj (HLSE:BIOBV)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Biohit Oyj is a biotechnology company that manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis to research institutions, healthcare, and industry worldwide with a market cap of €37.10 million.

Operations: The company's revenue is primarily generated from its Diagnostic Kits and Equipment segment, which accounts for €16.13 million.

Market Cap: €37.1M

Biohit Oyj, a biotechnology company, has demonstrated solid financial health with no debt and short-term assets of €7.4 million exceeding liabilities. The company reported half-year sales of €7.8 million and net income growth to €1.3 million, reflecting improved profit margins from 15.9% to 19.5%. Despite a low return on equity at 19.4%, Biohit's earnings have grown significantly over the past five years by an average of 54.1% annually, outpacing industry averages with recent annual growth at 38.4%. The board's experience and stable weekly volatility further support its investment appeal in the penny stock segment.

• Dive into the specifics of Biohit Oyj here with our thorough balance sheet health report.
• Assess Biohit Oyj's future earnings estimates with our detailed growth reports.

AcouSort (OM:ACOU)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: AcouSort AB (publ) is a technology company that develops components and instruments for the diagnostics, analytics, and cell therapy processing markets, with a market cap of SEK65.82 million.

Operations: The company's revenue is derived entirely from its Biotechnology segment, amounting to SEK9.31 million.

Market Cap: SEK65.82M

AcouSort AB, a technology firm in the diagnostics and cell therapy markets, operates with a market cap of SEK65.82 million and is currently pre-revenue, generating less than US$1 million annually. The company reported a second-quarter revenue decline to SEK2.14 million from SEK2.88 million year-over-year, alongside an increased net loss of SEK3.54 million. Despite this, AcouSort maintains financial stability with short-term assets surpassing liabilities and no long-term debt obligations. While its share price remains volatile and profitability elusive, the forecasted revenue growth of 56.87% per annum suggests potential for future expansion within the biotech sector.

• Click to explore a detailed breakdown of our findings in AcouSort's financial health report.
• Examine AcouSort's earnings growth report to understand how analysts expect it to perform.

AVTECH Sweden (OM:AVT B)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: AVTECH Sweden AB (publ) specializes in developing and selling products and services for digital air traffic management systems, with a market cap of SEK175.37 million.

Operations: The company generates revenue from its Aerospace & Defense segment, amounting to SEK55.16 million.

Market Cap: SEK175.37M

AVTECH Sweden AB, with a market cap of SEK175.37 million, has demonstrated consistent profitability growth over the past five years, achieving a 45.4% annual increase in earnings. Despite recent setbacks with LATAM Airlines affecting its recurring revenue by SEK8.5 million, AVTECH maintains strong financial health with no debt and substantial short-term assets exceeding liabilities by SEK44.6 million. The company benefits from an experienced board and management team and offers high-quality earnings supported by a favorable price-to-earnings ratio of 10.3x compared to the Swedish market average of 18.4x, although its share price remains highly volatile.

• Take a closer look at AVTECH Sweden's potential here in our financial health report.
• Gain insights into AVTECH Sweden's historical outcomes by reviewing our past performance report.

Taking Advantage

• Click here to access our complete index of 310 European Penny Stocks.
• Searching for a Fresh Perspective? Trump has pledged to "unleash" American oil and gas and these 80 US stocks have developments that are poised to benefit.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com